Advertisement

Cannabinoids to Treat Cannabis Use Disorders

  • Christina A. Brezing
  • Frances R. Levin
Chapter

Abstract

As with treatment development for other substance use disorders, there has been great interest in exploring the clinical use of cannabinoid agonists and antagonists for the treatment of cannabis use disorder (CUD). While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings has resulted in evidence demonstrating medications with cannabinoid receptor-1 (CB-1) activity are effective in the treatment of cannabis withdrawal, reduction of cannabis use, and prevention of relapse (in the human lab model) and hold a great promise for future work. As with other controlled prescriptions, off-label clinical use of cannabinoid agonists should be considered in the context of potential misuse, overuse, and diversion. While the antagonist medication rimonabant demonstrated early promise in the human lab, safety concerns and withdrawal of its use from the US market preclude further investigation of this agent. However, development of antagonists with different properties may have clinical utility, though they are in the earliest stages of preclinical investigation.

Keywords

Cannabinoids CB1 agonist CB1 antagonist Treatment 

References

  1. 1.
    Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, Booth J, McGregor IS. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiat. 2014;71:281–91.CrossRefGoogle Scholar
  2. 2.
    Balter RE, Cooper ZD, Haney M. Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep. 2014;1:137–43.CrossRefGoogle Scholar
  3. 3.
    Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol. 2013;18:872–81.CrossRefGoogle Scholar
  4. 4.
    Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94:1311–22.CrossRefGoogle Scholar
  5. 5.
    Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86:22–9.CrossRefGoogle Scholar
  6. 6.
    Elkashef A, Vocci F, Huestis M, Haney M, Budney A, Gruber A, el-Guebaly N. Marijuana neurobiology and treatment. Subst Abuse. 2008;29:17–29.CrossRefGoogle Scholar
  7. 7.
    Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, Loureiro M, Laviolette SR, Vemuri K, Makriyannis A, Le Foll B. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19:1–11.CrossRefGoogle Scholar
  8. 8.
    Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013;38:1557–65.CrossRefGoogle Scholar
  9. 9.
    Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2008;197:157–68.CrossRefGoogle Scholar
  10. 10.
    Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:158–70.CrossRefGoogle Scholar
  11. 11.
    Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016;41:1974–82.CrossRefGoogle Scholar
  12. 12.
    Haney M, Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology. 2008;199:403–19.CrossRefGoogle Scholar
  13. 13.
    Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology. 2005;181:237–43.CrossRefGoogle Scholar
  14. 14.
    Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology. 2002;164:407–15.CrossRefGoogle Scholar
  15. 15.
    Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology. 2016;233:2469–78.CrossRefGoogle Scholar
  16. 16.
    Hill KP, Palastro MD, Gruber SA, Fitzmaurice GM, Greenfield SF, Lukas SE, Weiss RD. Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addict. 2017;26:795–801.CrossRefGoogle Scholar
  17. 17.
    Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology. 2007;194:505–15.CrossRefGoogle Scholar
  18. 18.
    Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001;58:322–8.CrossRefGoogle Scholar
  19. 19.
    Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116:142–50.CrossRefGoogle Scholar
  20. 20.
    Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV, Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, Choi JC. Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2016;159:53–60.CrossRefGoogle Scholar
  21. 21.
    Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol. 2017;8:422.CrossRefGoogle Scholar
  22. 22.
    Roberfroid D, Lachat C, Lucet C. Termination of the CRESCENDO trial. Lancet. 2010;376:1983–4; author reply 1984–1985.CrossRefGoogle Scholar
  23. 23.
    Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, Barnes AJ, Huestis MA, Le Foll B. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 2016a;161:298–306.CrossRefGoogle Scholar
  24. 24.
    Trigo JM, Soliman A, Staios G, Quilty L, Fischer B, George TP, Rehm J, Selby P, Barnes AJ, Huestis MA, Le Foll B. Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a case series. J Addict Med. 2016b;10:274–9.CrossRefGoogle Scholar
  25. 25.
    Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117:38–44.CrossRefGoogle Scholar
  26. 26.
    Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013;128:64–70.CrossRefGoogle Scholar
  27. 27.
    Vermersch P. Sativex((R)) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert Rev Neurother. 2011;11:15–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.New York State Psychiatric Institute, Division of Substance Use DisordersNew YorkUSA
  2. 2.Department of PsychiatryCollege of Physicians and Surgeons of Columbia UniversityNew YorkUSA

Personalised recommendations